CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Pharma group Egetis soars after $547 million takeover  offer from ANI

By Reuters News

** Shares in Egetis Therapeutics EGTX.ST rise 11%, after the Swedish drug developer accepted a public cash offer from ANI Pharmaceuticals ANIP.O

** ANI offers a total of 5.30 billion Swedish crowns ($547 million) for all the shares in Egetis, with the price per share in the offer 12.6% above the closing price of 9.99 crowns on Wednesday

** Egetis recommends the offer to its shareholders, saying ANI is "well positioned" to accelerate the commercial launch of its Emcitate drug in the United States

** "We believe that ANI can provide the right capabilities for a successful commercialization of Emcitate", Van Lanschot Kempen analysts say

** The broker sees the offer as fair, adding it came earlier than expected

** Egetis shares rise 108% year to date

($1 = 9.6971 Swedish crowns)

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk